Update on dermal substitutes

Abstract

Tissue-engineered biological dressings offer promise in the treatment of burns, chronic ulcers, donor site and other surgical wounds, and a variety of dermatologic conditions. Despite this promise, cellular tissue-engineered products such a Dermagraft and Apligraf have suffered setbacks in recent years with a lower market share than the commercial promoters of these products anticipated. AlloDerm acellular dermal matrix, an older technology than these cell-based products, has made strong progress in winning over clinicians in various disciplines. Similarly, Integra Bilayer Matrix Wound Dressing (BMWD) continues to gain acceptance beyond its original burn audience. A review on the products is offered.